Extracellular heat shock proteins (HSP) have been shown to have a profound effect on tumor immunity. We have prepared a highly effective cancer vaccine by extracting Hsp70/Hsp90 complexes from the fusion of tumor cells and dendritic cells (Hsp70.PC-F).
We aim i n this proposal to examine the properties of the vaccine and optimize its use either solo or combined with ionizing radiation.
We aim first to understand the role of the receptor SRECI in dendritic cells (DC) in binding to Hsp70.PC-F and subsequent uptake and presentation of antigens to T lymphocytes.
We aim to determine how SRECI can orchestrate antigen cross presentation, innate immune stimulation and cell regulation in DC. Next, in the translational studies in Aim 2 we will examine the role of Hsp70.PC-F in treatment of spontaneous mammary carcinoma in mice.
We aim to determine treatment effectiveness and the degree to which vaccines can be used in combination with adjuvants such as TLR3 and TLR9 agonists as well as inhibitors of co-repressing molecule CTLA4. We will further determine whether vaccine design can be manipulated to give selective destruction of tumor initiating cells and radiation resistant cells that accumulate in fractionated radiation therapy.

Public Health Relevance

Immunotherapy and radiation therapy, when combined, may be highly effective in cancer therapy, as radiation can kill the majority of cells in the tumor whie immunotherapy is capable of targeting small colonies of disseminated cells (metastases). We have devised a novel vaccine with unique properties based on extracting heat shock proteins from tumors and injecting them into tumor bearing mice. We will determine the effectiveness of the vaccine in killing mouse mammary tumor cells alone or in combination with biological adjuvants and ionizing radiation.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01CA119045-08
Application #
8685149
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wong, Rosemary S
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Chou, S-D; Murshid, A; Eguchi, T et al. (2015) HSF1 regulation of ?-catenin in mammary cancer cells through control of HuR/elavL1 expression. Oncogene 34:2178-88
Eguchi, Takanori; Watanabe, Ken; Hara, Emilio Satoshi et al. (2013) OstemiR: a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesencymal stem cells. PLoS One 8:e58796
Weng, Desheng; Song, Baizheng; Koido, Shigeo et al. (2013) Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation. J Immunol 191:755-63
Murshid, Ayesha; Eguchi, Takanori; Calderwood, Stuart K (2013) Stress proteins in aging and life span. Int J Hyperthermia 29:442-7
Calderwood, Stuart K; Gong, Jianlin; Stevenson, Mary Ann et al. (2013) Cellular and molecular chaperone fusion vaccines: targeting resistant cancer cell populations. Int J Hyperthermia 29:376-9
Calderwood, Stuart K (2013) Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy. Discov Med 15:188-94
Murshid, Ayesha; Gong, Jianlin; Calderwood, Stuart K (2013) Purification, preparation, and use of chaperone-peptide complexes for tumor immunotherapy. Methods Mol Biol 960:209-17
Ciocca, Daniel R; Arrigo, Andre Patrick; Calderwood, Stuart K (2013) Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol 87:19-48
Calderwood, Stuart K (2012) Elevated levels of HSF1 indicate a poor prognosis in breast cancer. Future Oncol 8:399-401
Zhang, Yue; Murshid, Ayesha; Prince, Thomas et al. (2011) Protein kinase A regulates molecular chaperone transcription and protein aggregation. PLoS One 6:e28950

Showing the most recent 10 out of 21 publications